Abivax SA

As of June 30, 2026, Abivax SA carries a market capitalization of 9.22B, placing it among publicly traded companies globally. Its enterprise value stands at 8.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Abivax SA's next confirmed earnings release is scheduled for December 14, 2026.

As of June 30, 2026, Abivax SA has 79.82M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Abivax SA maintains a current ratio of 5.97, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.33, indicating conservative leverage, while an interest coverage ratio of -42.69 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Abivax SA posted a negative return on equity (ROE) of -40.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -31.70, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 69.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Abivax SA recorded an income tax benefit of -5.85M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -171.75M and -165.90M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Abivax SA's stock has gained approximately 8.83% over the past 52 weeks. The 50-day moving average sits at 90.94, while the 200-day moving average is 99.85.

Over the twelve months ended June 30, 2026, Abivax SA generated - - in revenue and converted that into -165.90M in net income, yielding earnings per share of -2.09. EBITDA reached -139.60M, while operating income came in at -140.34M.

As of June 30, 2026, Abivax SA holds 410.68M in cash and equivalents against 1.21M in total debt, resulting in a net debt position of -387.99M. Total book value stands at 366.27M, with working capital of 355.94M providing operational flexibility.

Abivax SA produced -102.51M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -166,000.00 in capital expenditures, free cash flow totaled -102.67M - equivalent to -1.29 per share.

Over the twelve months ended June 30, 2026, Abivax SA paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.43, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Abivax SA shareholders.

As of June 30, 2026, Abivax SA has an Altman Z-Score of 54.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.